<DOC>
	<DOCNO>NCT02192450</DOCNO>
	<brief_summary>The purpose study determine whether insulin degludec compare insulin glargine reduce risk symptomatic nocturnal hypoglycaemia subject greatest potential benefit optimised insulin treatment , patient type 1 diabetes high risk nocturnal severe hypoglycaemia .</brief_summary>
	<brief_title>Insulin Degludec Symptomatic Nocturnal Hypoglycaemia</brief_title>
	<detailed_description>Background : Insulin degludec novel insulin analogue may reduce risk mild nocturnal hypoglycaemia type 1 diabetes . Patients type 1 diabetes recurrent severe hypoglycaemia ( high risk patient ) also burden nocturnal hyoglycaemia ( mild silent ) . These episode may contribute developement hormonal counterregulatory failure hypoglycaemia unawareness , turn increase risk hypoglycaemic episode , especially epiosdes severe hypoglycaemia.The effect insulin degludec risk mild nocturnal hypoglycaemia subject type 1 diabetes high risk severe hypoglycaemia compare insulin glargine investigate . Study design intervention : A control , cross-over multi-centre study Prospective , Randomised , Open , Blinded Endpoint ( PROBE ) design . Each treatment period last 12 month . Patients randomise treatment basal-bolus therapy insulin aspart/degludec insulin aspart/glargine random order . Endpoints assess last 9 month treatment arm . Subjects : 175 type 1 diabetic patient history one episodes nocturnal severe hypoglycaemia proceed two year . Method : Patients record event symptomatic ( mild ) , asymptomatic ( silent ) severe hypoglycaemia diary . All event symptomatic nocturnal severe hypoglycaemia must also report telephone within 24 hour . Patients instructed record self-monitored blood glucose ( SMBG ) i.e . 4-point profile twice per week ( blood glucose breakfast , lunch , dinner bedtime ) . Outcomes : See `` Outcome Measures '' . Concerning primary endpoint possible symptomatic nocturnal hypoglycaemic episode adjudicate independent endpoint committee consist diabetes specialist blind individual patient insulin regimen . Safety : Adverse reaction</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes &gt; 5 year One episodes nocturnal severe hypoglycaemia precede two year Treated multiple dose insulin injection ( &gt; 2 ) insulin pump . Both human insulin insulin analogue allow Willingness daily ( OD ) regimen concern insulin degludec insulin glargine Willingness selfmonitoring blood glucose ( SMBG ) keep diary Signed inform consent History primary secondary adrenal insufficiency , growth hormone deficiency , untreated myxoedema History unstable angina major cardiovascular event ( myocardial infarction , coronary revascularisation , transient ischaemic attack , stroke within last three month ) Heart failure , New York Heart Association ( NYHA ) class IV History malignancy unless diseasefree period exceed five year History alcohol drug abuse Treatment glucose lower agent ( ) insulin Pregnant lactate woman Women childbearing potential use chemical ( Ppills gestagen depot ) mechanical ( intrauterine device ) contraception Participation another investigational drug study within last 3 month Inability understand inform consent HbA1c &gt; 86 mmol/mol ( 10 % ) Shifting work hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Hypoglycaemia</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Insulin</keyword>
	<keyword>Hypoglycaemic Agents</keyword>
	<keyword>Physiological Effetcs Drugs</keyword>
</DOC>